Home
Medical Courses
Webinars
Self-development
My Activity
Understanding Alk+ NSCLC

Understanding Alk+ NSCLC

Oncology
A badge with ribbon in color black No CME/CPD credits | An analog clock in color black 45 Minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 04 Mar 2027 

Overview

Course Overview

This educational module explores ALK-positive non-small cell lung cancer (NSCLC), a distinct molecular subtype associated with younger, non-smoking patients. With a focus on molecular pathogenesis, diagnostic testing, treatment evolution, and the latest evidence from the CROWN trial, learners will gain insights into optimal patient management using next-generation ALK inhibitors like lorlatinib.

The course highlights the unmet needs in ALK+ NSCLC, especially regarding central nervous system (CNS) involvement, and presents the 5-year efficacy and safety findings that support lorlatinib as a frontline option.

Learning Objectives

By the end of this course, learners will be able to:

  1. Recognize the clinical characteristics and diagnostic criteria for ALK+ NSCLC.
  2. Understand the evolution of ALK-targeted therapies and resistance mechanisms.
  3. Evaluate the efficacy and safety data supporting lorlatinib use in ALK+ NSCLC.
  4. Apply real-world considerations in molecular testing and CNS disease management.

Topics covered

  1. Epidemiology and pathophysiology of ALK+ NSCLC and the role of ALK
  2. Diagnostic Testing for ALK
  3. Unmet Needs in ALK+ NSCLC
  4. CROWN Study Overview
  5. CROWN Study Efficacy Analysis
  6. CROWN Study Safety Analysis
  7. CROWN Study Dose Reduction 16-week Efficacy Analysis
  8. CROWN Study Genomic Analysis
  9. CROWN Study Summary
Something went wrong.